vs

Side-by-side financial comparison of DUOS TECHNOLOGIES GROUP, INC. (DUOT) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $9.5M, roughly 1.3× DUOS TECHNOLOGIES GROUP, INC.). DUOS TECHNOLOGIES GROUP, INC. runs the higher net margin — -33.8% vs -1398.3%, a 1364.5% gap on every dollar of revenue. On growth, DUOS TECHNOLOGIES GROUP, INC. posted the faster year-over-year revenue change (547.5% vs 434.0%). DUOS TECHNOLOGIES GROUP, INC. produced more free cash flow last quarter ($-18.6M vs $-156.9M). Over the past eight quarters, DUOS TECHNOLOGIES GROUP, INC.'s revenue compounded faster (149.0% CAGR vs 138.5%).

DUOS Technologies Group Inc. develops and deploys AI-powered automation, inspection, and security solutions for railway transportation, critical infrastructure, and commercial clients across North America. Its offerings include real-time monitoring systems and safety tools that help customers boost efficiency, reduce risks, and strengthen site security.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

DUOT vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.3× larger
RNA
$12.5M
$9.5M
DUOT
Growing faster (revenue YoY)
DUOT
DUOT
+113.4% gap
DUOT
547.5%
434.0%
RNA
Higher net margin
DUOT
DUOT
1364.5% more per $
DUOT
-33.8%
-1398.3%
RNA
More free cash flow
DUOT
DUOT
$138.3M more FCF
DUOT
$-18.6M
$-156.9M
RNA
Faster 2-yr revenue CAGR
DUOT
DUOT
Annualised
DUOT
149.0%
138.5%
RNA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DUOT
DUOT
RNA
RNA
Revenue
$9.5M
$12.5M
Net Profit
$-3.2M
$-174.4M
Gross Margin
26.7%
Operating Margin
-36.1%
-1513.5%
Net Margin
-33.8%
-1398.3%
Revenue YoY
547.5%
434.0%
Net Profit YoY
6.1%
-117.0%
EPS (diluted)
$-0.10
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DUOT
DUOT
RNA
RNA
Q4 25
$9.5M
Q3 25
$6.9M
$12.5M
Q2 25
$5.7M
$3.8M
Q1 25
$5.0M
$1.6M
Q4 24
$1.5M
$3.0M
Q3 24
$3.2M
$2.3M
Q2 24
$1.5M
$2.0M
Q1 24
$3.5M
Net Profit
DUOT
DUOT
RNA
RNA
Q4 25
$-3.2M
Q3 25
$-1.0M
$-174.4M
Q2 25
$-3.5M
$-157.3M
Q1 25
$-2.1M
$-115.8M
Q4 24
$-3.4M
$-102.3M
Q3 24
$-1.4M
$-80.4M
Q2 24
$-3.2M
$-70.8M
Q1 24
$-68.9M
Gross Margin
DUOT
DUOT
RNA
RNA
Q4 25
26.7%
Q3 25
36.6%
Q2 25
26.5%
Q1 25
26.5%
Q4 24
-22.6%
Q3 24
28.4%
Q2 24
-14.2%
Q1 24
Operating Margin
DUOT
DUOT
RNA
RNA
Q4 25
-36.1%
Q3 25
-16.2%
-1513.5%
Q2 25
-60.0%
-4448.7%
Q1 25
-36.1%
-8360.9%
Q4 24
-211.2%
-4069.6%
Q3 24
-59.3%
-4200.9%
Q2 24
-212.9%
-4040.4%
Q1 24
-2178.6%
Net Margin
DUOT
DUOT
RNA
RNA
Q4 25
-33.8%
Q3 25
-15.1%
-1398.3%
Q2 25
-61.3%
-4089.3%
Q1 25
-42.0%
-7360.0%
Q4 24
-233.2%
-3439.5%
Q3 24
-43.3%
-3441.7%
Q2 24
-212.1%
-3461.8%
Q1 24
-1943.4%
EPS (diluted)
DUOT
DUOT
RNA
RNA
Q4 25
$-0.10
Q3 25
$-0.06
$-1.27
Q2 25
$-0.30
$-1.21
Q1 25
$-0.18
$-0.90
Q4 24
$-0.40
$-0.80
Q3 24
$-0.18
$-0.65
Q2 24
$-0.43
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DUOT
DUOT
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$48.6M
$1.9B
Total Assets
$63.4M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DUOT
DUOT
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$613.6K
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Stockholders' Equity
DUOT
DUOT
RNA
RNA
Q4 25
$48.6M
Q3 25
$49.5M
$1.9B
Q2 25
$4.7M
$1.2B
Q1 25
$5.2M
$1.3B
Q4 24
$2.3M
$1.4B
Q3 24
$2.5M
$1.5B
Q2 24
$2.9M
$1.2B
Q1 24
$830.9M
Total Assets
DUOT
DUOT
RNA
RNA
Q4 25
$63.4M
Q3 25
$69.8M
$2.1B
Q2 25
$31.1M
$1.4B
Q1 25
$34.1M
$1.5B
Q4 24
$35.0M
$1.6B
Q3 24
$22.0M
$1.6B
Q2 24
$21.2M
$1.3B
Q1 24
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DUOT
DUOT
RNA
RNA
Operating Cash FlowLast quarter
$-2.7M
$-156.2M
Free Cash FlowOCF − Capex
$-18.6M
$-156.9M
FCF MarginFCF / Revenue
-196.3%
-1257.6%
Capex IntensityCapex / Revenue
167.6%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-37.4M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DUOT
DUOT
RNA
RNA
Q4 25
$-2.7M
Q3 25
$-3.2M
$-156.2M
Q2 25
$-3.2M
$-199.7M
Q1 25
$-4.7M
$-124.8M
Q4 24
$2.7M
$-99.9M
Q3 24
$-2.3M
$-65.6M
Q2 24
$-1.9M
$-65.0M
Q1 24
$-70.4M
Free Cash Flow
DUOT
DUOT
RNA
RNA
Q4 25
$-18.6M
Q3 25
$-9.6M
$-156.9M
Q2 25
$-4.0M
$-203.0M
Q1 25
$-5.2M
$-128.6M
Q4 24
$2.4M
$-103.8M
Q3 24
$-2.9M
$-67.3M
Q2 24
$-2.8M
$-65.5M
Q1 24
$-71.3M
FCF Margin
DUOT
DUOT
RNA
RNA
Q4 25
-196.3%
Q3 25
-139.7%
-1257.6%
Q2 25
-69.6%
-5277.1%
Q1 25
-105.9%
-8174.3%
Q4 24
166.2%
-3491.0%
Q3 24
-90.2%
-2881.8%
Q2 24
-184.3%
-3204.6%
Q1 24
-2012.3%
Capex Intensity
DUOT
DUOT
RNA
RNA
Q4 25
167.6%
Q3 25
93.8%
5.7%
Q2 25
13.8%
86.9%
Q1 25
11.6%
238.6%
Q4 24
19.5%
131.7%
Q3 24
20.5%
72.9%
Q2 24
58.0%
26.0%
Q1 24
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DUOT
DUOT

Services And Consulting Related Parties$8.5M90%
Other$929.3K10%

RNA
RNA

Segment breakdown not available.

Related Comparisons